Clara Allayous

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

Inês Pires da Silva, Tasnia Ahmed, Irene L. M. Reijers et al. · The Lancet Oncology · 2021 · 215 citations

Medicine, Oncology, Pharmacotherapy +16

Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma

C. Owen, Xue Bai, Serigne Lo et al. · Annals of Oncology · 2021 · 184 citations · Full text

Medicine, Immunology, Oncology +14

Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders

Lauren Brown, Alison M. Weppler, Prachi Bhave et al. · Journal for ImmunoTherapy of Cancer · 2021 · 90 citations · Full text

Life Sciences, Immunology, Oncology +17

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma

Prachi Bhave, Tasnia Ahmed, Serigne Lo et al. · Journal for ImmunoTherapy of Cancer · 2022 · 65 citations · Full text

Life Sciences, Oncology, Pharmacotherapy +17

Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis

Prachi Bhave, Lalit Pallan, Georgina V. Long et al. · British Journal of Cancer · 2020 · 63 citations · Full text

Pharmacy, Immunology, Oncology +17